Osteoarthritis and Cartilage · Apr 2025
Scientific paper describing RM-010 as a capsaicin controlled-release system for chronic knee osteoarthritis pain and listing Relevium-affiliated authors.
Platform injectable gel based therapeutic for osteoarthritis
Company research
Public company, workplace, funding, and market signals
Overview
Galway-based University of Galway spinout developing RM-010, a hydrogel-based, non-opioid treatment platform for chronic pain, with a lead focus on knee osteoarthritis.
Primary product
RM-010 injectable hydrogel for knee osteoarthritis pain relief
Founded
2019
Headquarters
Galway, Ireland
Team size
1-10
Industry
Pharmaceutical Manufacturing
Sub-industry
Biopharmaceuticals / chronic-pain therapeutics
Offices
Unit 203B, Business Innovation Centre, University of Galway, Upper Newcastle, Galway, H91 NY52, Ireland
Open Positions
0 jobs at Relevium Medical
No open positions
Check back later for new openings